首页> 外文OA文献 >Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ge;70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy

【2h】

Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ge;70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy

机译：1090中的Alirocumab或Evolocumab治疗的资格在1090例高胆固醇患者中提到了含有LDL胆固醇≥70mg/ dl的区域胆固醇治疗中心，尽管最大耐受LDL-胆固醇降低治疗

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Vybhav Jetty; Charles Glueck; Kevin Lee; Naila Goldenberg; Marloe Prince; Ashwin Kumar; Michael Goldenberg; Ishan Anand; Ping Wang;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy [J] . Vybhav Jetty, Charles J Glueck, Kevin Lee, Vascular Health and Risk Management . 2017,第4期

机译：尽管最大耐受性降低LDL胆固醇的疗法，但仍向LDL胆固醇≥70 mg / dL的地区胆固醇治疗中心推荐的1090名高胆固醇血症患者接受alirocumab或evolocumab治疗
2. ELIGIBILITY FOR PCSK9 INHIBITOR TREATMENT IN 1090 HYPERCHOLESTEROLEMIC PATIENTS REFERRED TO A REGIONAL CHOLESTEROL TREATMENT CENTER WITH LDL CHOLESTEROL = 70 MG/DL DESPITE MAXIMAL TOLERATED CHOLESTEROL LOWERING THERAPY [J] . Milgrom A., Min S., Duhon G., Journal of investigative medicine . 2017,第4期

机译：1090例高胆固醇患者的PCSK9抑制剂治疗的资格提到了具有LDL胆固醇的区域胆固醇治疗中心，= 70mg / DL，尽管最大耐受性胆固醇降低治疗
3. ELIGIBILITY FOR PCSK9 TREATMENT IN 734 HYPERCHOLESTEROLEMIC PATIENTS REFERRED TO A REGIONAL CHOLESTEROL TREATMENT CENTER WITH LDL CHOLESTEROL >= 70 MG/DL DESPITE MAXIMAL TOLERATED CHOLESTEROL LOWERING THERAPY [J] . Shah P., Glueck C. J., Goldenberg N., Journal of investigative medicine . 2016,第4期

机译：在LDL胆固醇大于等于70 MG / DL的区域性胆固醇治疗中心治疗的734例胆固醇高的患者中PCSK9治疗的合格率
4. Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy [O] . Vybhav Jetty, Charles J Glueck, Kevin Lee, 2017

机译：尽管耐受性最大的降低LDL胆固醇的疗法但仍向LDL胆固醇≥70 mg / dL的地区胆固醇治疗中心推荐的1090名高胆固醇血症患者接受alirocumab或evolocumab治疗
5. Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dl despite maximal tolerated cholesterol lowering therapy [O] . Charles J. Glueck, Parth Shah, Naila Goldenberg, 2016

机译：尽管有最大的降低胆固醇耐受性的治疗方法，但还是有LDL胆固醇≥70mg / dl的地区胆固醇治疗中心的734名高胆固醇血症患者接受PCSK9治疗的资格

Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ge;70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy

著录项

相似文献

相关主题

期刊订阅